实用医学杂志 ›› 2021, Vol. 37 ›› Issue (18): 2355-2359.doi: 10.3969/j.issn.1006⁃5725.2021.18.010

• 临床研究 • 上一篇    下一篇

基因检测指导下非瓣膜性房颤患者华法林抗凝治疗的研究

朱业1,2 刘佳1,3 谷慧阳1,2 陈佳杉1,2 顾翔1,2   

  1. 1 扬州大学临床医学院(江苏扬州 225001);苏北人民医院2 心血管内科,3 药学部(江苏扬州 225001)

  • 出版日期:2021-09-25 发布日期:2021-09-25
  • 通讯作者: 顾翔 E⁃mail:guxiang@yzu.edu.cn;刘佳 E⁃mail:liujia85912@163.com
  • 基金资助:
    国家自然基金青年科学基金项目(编号:81800250);江苏省药学会课题(编号:Q2018088);扬州市“十三五”科教强卫专项(编号:医学重点人才 ZDRC20181);扬州市科技计划社会发展项目(编号:YZ2020074)

Effects and safety of genotype⁃guided warfarin anticoagulation in patients with nonvalvular atrial fibrilla⁃ tion

ZHU Ye*,LIU Jia,GU Huiyang,CHEN Jiashan,GU Xiang.   

  1. *Clinical Medical College of Yangzhou Univer⁃ sity,Yangzhou 225001,China;*Department of Cardiovascular Medicine,Northern Jiangsu People′ s Hospital Yangzhou 225001,China 

  • Online:2021-09-25 Published:2021-09-25
  • Contact: GU Xiang E⁃mail:guxiang@yzu.edu.cn;LIU Jia E⁃mail:liujia85912@163.com

摘要:

目的 研究基因检测指导下中国老年非瓣膜性心房颤动患者的华法林抗凝治疗的有效性和安全性。方法 所有非瓣膜性房颤患者随机分为基因检测组和对照组,基因检测组抽取患者外周静脉血用于测VKORC1、CYP2C9基因和国际标准化比值(international normalized ratio,INR),记录患者的临床资料。基因检测组根据华法林预测模型计算给药剂量,对照组经验性给药,后期两组患者均根据国际标准化比值(interna⁃ tional normalized ratio,INR)调整华法林剂量。对两组患者进行随访观察及华法林抗凝治疗质量评价。结果 基因检测组的过度抗凝和抗凝不足事件发生率均低于对照组(P < 0.05)。基因检测组前1个月、前3个月的INR值在目标范围时间(time in therapeutic range,TTR)的百分比均明显高于对照组。基因检测组的缺血性卒中事件累积发生率明显低于对照组。结论 基因检测指导下非瓣膜性房颤患者的华法林抗凝治疗可提高治疗安全性,提高平均TTR,且TTR在抗凝初期就能达到较高的水平,显著降低缺血性脑卒中事件的发生风险。

关键词: 心房颤动,  , 华法林,  , 基因检测

Abstract:

Objective To assess the effects of genotype⁃guided warfarin anticoagulation in Chinese elderly patients with nonvalvular atrial fibrillation(AF). Methods All the nonvalvular AF patients were assigned into two group shaving their warfarin dose determined by an algorithm using genetic and clinical factors(genetic group)or the same algorithm using clinical factors only(control group). For those in the genetic group,we also included genotypes for CYP2C9 and VKORC1.Genomic DNA was extracted from peripheral blood samplefor patients from genetic group using standard protocols. In the control group,the physicians and pharmacists determining the initial doses used the warfarin dosing algorithm to determine patients′ initial warfarin doses. Further dose adjustments in both groups used INR measurements and standard protocols. Results The incidence of over ⁃anticoagulant and under ⁃ anticoagulant events in genetic group was lower than that in control group(P < 0.05). The percentage of INR value in the the rapeutic range(TTR)in the first 1 month and 3 months of the genome was significantly higher than that in the control group. The cumulative incidence of ischemic stroke events occurred in the genetic group was significantly lower than that in the control group. Conclusion Genotype⁃guided dosing could improve the average TTR,improve the safety of treatment,increase the average TTR and the TTR can reach a higher level in the early stage of anticoagulation and resulted in a lower risk of ischemic stroke events significantly.

Key words:

atrial fibrillation, warfarin, genetype?guided